Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS 株式レポート

時価総額：US$1.8b

Tarsus Pharmaceuticals マネジメント

マネジメント 基準チェック /44

Tarsus Pharmaceuticalsの CEO はBobby Azamianで、 Nov2016年に任命され、 の在任期間は 7.92年です。 の年間総報酬は$ 3.13Mで、 19.8%給与と80.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.25%を直接所有しており、その価値は$ 40.08M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と4.1年です。

主要情報

Bobby Azamian

最高経営責任者

US$3.1m

報酬総額

CEO給与比率19.8%
CEO在任期間8yrs
CEOの所有権2.3%
経営陣の平均在職期間3.5yrs
取締役会の平均在任期間4.1yrs

経営陣の近況

Recent updates

Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Nov 07
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Nov 05
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Sep 05
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 20

With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Jun 26
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

CEO報酬分析

Tarsus Pharmaceuticals の収益と比較して、Bobby Azamian の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$148m

Dec 31 2023US$3mUS$620k

-US$136m

Sep 30 2023n/an/a

-US$108m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$65m

Dec 31 2022US$4mUS$590k

-US$62m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$7mUS$550k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$3mUS$437k

-US$27m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$416kUS$300k

-US$5m

報酬と市場: Bobbyの 総報酬 ($USD 3.13M ) は、 US市場 ($USD 5.54M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Bobbyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Bobby Azamian

8yrs

在職期間

US$3,130,332

報酬

Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bobak Azamian
Co-Founder8yrsUS$3.13m2.25%
$ 40.1m
Jeffrey S. Farrow
CFO & Chief Strategy Officer1.6yrsUS$3.99m0.048%
$ 848.5k
Seshadri Neervannan
Chief Operating Officer4.3yrsUS$1.74m0.17%
$ 3.0m
Elizabeth Yeu
Chief Medical Officer & Director4.3yrsUS$180.21k0.087%
$ 1.6m
David Nakasone
Head of Investor Relations3.2yrsデータなしデータなし
Bryan Wahl
General Counsel & Corporate Secretary3.8yrsUS$2.53m0.11%
$ 1.9m
Adrienne Kemp
Senior Director of Corporate Communications2.6yrsデータなしデータなし
Matthew Rossen
Vice President of Marketing2.8yrsデータなしデータなし
Scott Youmans
Vice President of Sales2.7yrsデータなしデータなし
Dianne Whitfield
Chief Human Resources Officer3.8yrsUS$3.21m0.090%
$ 1.6m
Aziz Mottiwala
Chief Commercial Officer4.3yrsデータなし0.14%
$ 2.5m
Cara Miller
Senior Vice President of Corporate Affairs1.1yrsデータなしデータなし

3.5yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: TARSの経営陣は 経験豊富 であると考えられます ( 3.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Bobak Azamian
Co-Founder7.9yrsUS$3.13m2.25%
$ 40.1m
Elizabeth Yeu
Chief Medical Officer & Director2.8yrsUS$180.21k0.087%
$ 1.6m
William Link
Independent Director7.8yrsUS$183.33k0.47%
$ 8.3m
Wendy Yarno
Lead Independent Director4yrsUS$265.83k0.027%
$ 484.3k
Bhaskar Chaudhuri
Independent Director4.9yrsUS$178.58k0.014%
$ 250.3k
Scott William Morrison
Independent Director2.1yrsUS$186.46k0.016%
$ 281.4k
Rosemary Crane
Independent Director3.3yrsUS$183.71k0.014%
$ 250.3k
Andrew Goldberg
Independent Director4.3yrsUS$171.71k0.017%
$ 297.1k

4.1yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: TARSの 取締役会 は 経験豊富 であると考えられます ( 4.1年の平均在任期間)。